Product Images Meloxicam

Not available.*

This text provides important cautionary information about the use of NSAIDs (nonsteroidal anti-inflammatory drugs). It warns against taking higher doses of NSAIDs and using them for extended periods of time. It also advises against taking NSAIDs before or after a heart surgery called coronary artery bypass graft (CABG). Furthermore, it suggests avoiding NSAIDs after a recent heart attack unless specifically instructed by a healthcare provider due to an increased risk of another heart attack.*

This text appears to be a cautionary message regarding the use of certain medications. It highlights the potential risks associated with using NSAIDs (nonsteroidal anti-inflammatory drugs) such as the increased risk of ulcers or bleeding. The text mentions several factors that can heighten this risk, including a history of stomach ulcers or bleeding, the use of certain medications like corticosteroids or anticoagulants, increasing doses or prolonged use of NSAIDs, smoking, alcohol consumption, older age, poor health, advanced liver disease, and bleeding problems. It advises to be cautious and seek medical attention if any warning symptoms occur as these risks can potentially lead to death.*

This text appears to be a list of symptoms or warning signs related to possible health issues. Some of the mentioned symptoms include nausea, fatigue, diarrhea, itching, yellowing of the skin or eyes, indigestion or stomach pain, flu-like symptoms, vomiting blood, presence of blood in bowel movements (appearing black and sticky like tar), unusual weight gain, skin rash or blisters accompanied by fever, and swelling of the arms, legs, hands, and feet. These symptoms may indicate the need for medical attention or further evaluation by a healthcare professional.*

Table la provides information on the adverse events occurring in 22% of patients taking Meloxicam in a 12-week osteoarthritis placebo- and active-controlled trial. The table compares the occurrence of these events between the placebo group, the Meloxicam group, and the Diclofenac group. The adverse events include gastrointestinal issues, abdominal pain, diarrhea, accident household, edemal, fall, influenza-like symptoms, central and peripheral nervous system issues (such as dizziness and headache), respiratory issues (such as pharyngitis and upper respiratory tract infection), and skin issues (such as rash).*

Table 1b displays the percentage of adverse events occurring in more than 2% of patients taking Meloxicam in two 12-week placebo-controlled trials for Rheumatoid Arthritis. The table includes data for patients taking a daily dose of 7.5mg and 15mg of Meloxicam. The number of patients in each group is provided, along with the percentages of adverse events in various categories. These categories include gastrointestinal disorders, general disorders and administration site conditions, infection and infestations, musculoskeletal and connective tissue disorders, nervous system disorders, and skin and subcutaneous conditions. The specific adverse events listed in the table are abdominal pain, dyspeptic signs and symptoms, influenza-like illness, upper respiratory tract infections, joint-related signs and symptoms, headaches, and rash. The table also mentions the MedDRA (Medical Dictionary for Regulatory Activities) preferred terms for some of these adverse events.*

Description: This text appears to be a list of various side effects or symptoms related to different body systems. Some examples include allergic reactions, fatigue, weight changes, cardiovascular issues such as hypertension or myocardial infarction, gastrointestinal problems like ulcers or hemorrhage, respiratory difficulties such as asthma, skin issues like alopecia or itching, and urinary problems such as increased levels of albumin or creatinine. It also mentions nervous system symptoms, hematologic changes, metabolic and nutritional issues, psychiatric symptoms, and abnormalities in special senses. Overall, this text seems to provide a comprehensive list of potential side effects or symptoms that can occur in different body systems.*

Table 2 provides information on the adverse events reported by patients taking Meloxicam in 4 to 6-week and 6-month active-controlled osteoarthritis trials. The table lists the percentage of patients experiencing each adverse event. The adverse events with an occurrence rate above 2% for Meloxicam patients include gastrointestinal issues such as abdominal pain, constipation, diarrhea, and dyspepsia. Other reported adverse events include dizziness, headache, anemia, muscular pain, back pain, insomnia, coughing, respiratory tract issues, skin-related issues such as pruritus and rash, and urinary tract infections. The combined WHO preferred terms for edema and rash are also mentioned.*

Tithium and Meloxicam: Concomitant use of Meloxicam and Tithium may lead to increased Tithium levels in the blood and decreased renal clearance. This can be attributed to the inhibition of renal prostaglandin synthesis by Meloxicam. It is important to monitor patients for signs of Tithium toxicity during this combination. Methotrexate and Meloxicam: The simultaneous use of Methotrexate and Meloxicam may increase the risk of Methotrexate toxicity, including conditions like neutropenia, thrombocytopenia, and renal dysfunction. Therefore, patients should be monitored for Methotrexate toxicity when using both these drugs. Cyclosporine and Meloxicam: Concurrent use of Cyclosporine and Meloxicam can potentially increase the nephrotoxicity of Cyclosporine. Therefore, it is essential to monitor patients for signs of worsening renal function during this combination. NSAIDs and Salicylates: Combinations of Meloxicam with other NSAIDs or salicylates (such as diflunisal or salsalate) can elevate the risk of gastrointestinal toxicity without any significant increase in efficacy. Hence, it is not recommended to use Meloxicam with other NSAIDs or salicylates. Pemetrexed and Meloxicam: The concomitant use of Pemetrexed and Meloxicam may increase the risk of Pemetrexed-associated myelosuppression, renal toxicity, and gastrointestinal toxicity. Patients with renal impairment should be closely monitored for myelosuppression and toxicity. Additionally, dosing of Meloxicam should be interrupted before and after Pemetrexed administration. In individuals with creatinine clearance below 45 mL/min, the concomitant administration of Meloxicam and Pemetrexed is not recommended.*

Table 3 provides information on significant drug interactions with Meloxicam. One important interaction is with anticoagulants, such as warfarin, which can increase the risk of serious bleeding when taken together with Meloxicam. Patients should be monitored for signs of bleeding when using these medications together. Additionally, the concomitant use of drugs that interfere with serotonin reuptake, such as selective serotonin reuptake inhibitors (SSRIs), can potentiate the risk of bleeding when taken with Meloxicam. Another interaction to note is that the concomitant use of NSAIDs, including Meloxicam, and aspirin can increase the risk of gastrointestinal adverse reactions compared to using the NSAID alone. Therefore, it is generally not recommended to use Meloxicam with low-dose or analgesic doses of aspirin due to the increased risk of bleeding. It is important to mention that Meloxicam is not a substitute for low-dose aspirin for cardiovascular protection. Meloxicam may also diminish the antihypertensive effect of ACE inhibitors, angiotensin receptor blockers (ARBs), or beta-blockers. In elderly patients, those who are volume-depleted or have renal impairment, the concomitant use of NSAIDs with ACE inhibitors or ARBs may lead to deterioration of renal function. Blood pressure should be monitored during the concomitant use of Meloxicam with ACE inhibitors, ARBs, or beta-blockers, and signs of worsening renal function should be observed. Additionally, it has been observed that NSAIDs can reduce the natriuretic effect of loop diuretics and thiazide diuretics in some patients. This effect is attributed to the NSAID inhibition of renal prostaglandin synthesis. However, studies with furosemide and Meloxicam have not shown a reduction in the natriuretic effect. Patients using Meloxicam with diuretics should be monitored for signs of worsening renal function and to ensure diuretic efficacy.*

Not available.*